Thomas Witzig
Mayo Clinic · The Mayo Clinic & Foundation · Eastern Cooperative Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Witzig as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:37 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02652715 · Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaMayo Clinic · completed · Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma · principal investigator
- Early Ph1NCT01719250 · Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaMayo Clinic · completed · Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma · principal investigator
- Ph3NCT01662102 · Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)Spectrum Pharmaceuticals, Inc · terminated · Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT00438880 · Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaMayo Clinic · completed · Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma · principal investigator
- Ph2NCT00088881 · Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaNational Cancer Institute (NCI) · terminated · Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma · principal investigator
- Ph1/Ph2NCT00012298 · Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNational Cancer Institute (NCI) · terminated · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Signal transduction inhibitor therapy for LymphomaR01CA127433 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2007 to 2011 · $325,779 awarded in 2011Same name and institution; not confirmed by an ID
- PI3K Pathway Inhibitors for Mantle Cell LymphomaR21CA112904 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2005 to 2006 · $239,509 awarded in 2006Same name and institution; not confirmed by an ID
- CHARACTERIZATION AND GROWTH OF CLONALLY RELATED MYELOMA CELLP01CA062242 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2002 to 2003 · $228,401 awarded in 2003Same name and institution; not confirmed by an ID
- HEMATOLOGYU10CA025224 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2002 · $78,870 awarded in 2002Same name and institution; not confirmed by an ID
- Radioimmunotherapy for LymphomaR21CA087912 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2001 to 2002 · $251,682 awarded in 2002Same name and institution; not confirmed by an ID
- APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCERR21CA078899 · NCI · MAYO CLINIC ROCHESTER · fiscal years 1998 to 1999 · $141,466 awarded in 1999Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 2012 to 2013Named on NCT00088881
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:37 UTC. The ranking covers the 200 most relevant of 137 PubMed records, and a shared surname and initials can bring in a namesake. All 137 on PubMed
- 5,007 citationsRCR 162.2
- 899 citationsRCR 18.3
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood · 2005518 citationsRCR 10.6
- A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.N Engl J Med · 1997511 citationsRCR 16.0
- Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.J Clin Oncol · 2002483 citationsRCR 10.2
- Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.J Clin Oncol · 1999442 citationsRCR 10.2
- Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.J Clin Oncol · 2002414 citationsRCR 8.6
- Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.J Clin Oncol · 2014366 citationsRCR 10.3
- 364 citationsRCR 10.3
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Ann Oncol · 2011329 citationsRCR 7.9